Combination adriamycin/misonidazole toxicity in V79 spheroids. 1982

R E Durand, and S M Brown

The internal, hypoxic cells of V79 spheroids are preferentially killed by misonidazole, whereas adriamycin is preferentially toxic to the external cells due to diffusion limitations. Evaluation of combination treatments with misonidazole and adriamycin was therefore undertaken in an attempt to optimize and equalize cell killing throughout these spheroids. A fluorescence-activated cell sorter was used to select cells as a function of intracellular adriamycin or Hoechst-33342 fluorescence (and, therefore, as a function of location in the spheroid) for subsequent viability determinations. As expected, preferential toxicity of each agent was easily demonstrable, and with prolonged treatment times with both agents, greater uniformity of killing was achieved throughout the spheroid. Additionally, some suggestion of enhanced adriamycin toxicity to aerobic cells of spheroids chronically exposed to misonidazole was observed, analogous to the increased radiation sensitivity previously reported for similar exposure conditions. These results demonstrate that combinations of chemotherapeutic agents can be chosen to have preferential activity against different subpopulations of cells within V79 spheroids. Presumably, a better understanding of the factors contributing to drug resistance will lead to the application of similar principles for human cancer therapy.

UI MeSH Term Description Entries
D008920 Misonidazole A nitroimidazole that sensitizes normally radio-resistant hypoxic cells to radiation. It may also be directly cytotoxic to hypoxic cells and has been proposed as an antineoplastic. Ro 07-0582,Ro 7-0582,alpha-(Methoxymethyl)-2-nitro-1H-imidazole-1-ethanol,Ro 07 0582,Ro 070582,Ro 7 0582,Ro 70582
D009374 Neoplasms, Experimental Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms. Experimental Neoplasms,Experimental Neoplasm,Neoplasm, Experimental
D009593 Nitroimidazoles IMIDAZOLES having a nitro moiety. Nitroimidazole
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D003412 Cricetulus A genus of the family Muridae consisting of eleven species. C. migratorius, the grey or Armenian hamster, and C. griseus, the Chinese hamster, are the two species used in biomedical research. Hamsters, Armenian,Hamsters, Chinese,Hamsters, Grey,Armenian Hamster,Armenian Hamsters,Chinese Hamster,Chinese Hamsters,Grey Hamster,Grey Hamsters,Hamster, Armenian,Hamster, Chinese,Hamster, Grey
D004273 DNA, Neoplasm DNA present in neoplastic tissue. Neoplasm DNA
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D006224 Cricetinae A subfamily in the family MURIDAE, comprising the hamsters. Four of the more common genera are Cricetus, CRICETULUS; MESOCRICETUS; and PHODOPUS. Cricetus,Hamsters,Hamster
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

R E Durand, and S M Brown
January 1982, International journal of radiation oncology, biology, physics,
R E Durand, and S M Brown
May 1982, British journal of cancer,
R E Durand, and S M Brown
January 1987, Cancer chemotherapy and pharmacology,
R E Durand, and S M Brown
August 1982, In vitro,
R E Durand, and S M Brown
November 1983, Radiation research,
R E Durand, and S M Brown
August 1979, International journal of radiation oncology, biology, physics,
R E Durand, and S M Brown
December 1981, British journal of cancer,
Copied contents to your clipboard!